Looking ahead, rngen is committed to expanding our research and development efforts to address a broader range of health challenges. Our future plans include advancing our drug candidates through clinical trials and exploring new therapeutic areas. We will continue to drive meaningful change in the healthcare sector by focusing on innovation and collaboration.

rngen is strategically positioned to become a leader in next-generation, systems pharmacology-driven drug discovery. With a pipeline of innovative therapies and a clear clinical roadmap, we aim to accelerate development, secure strategic partnerships, and deliver transformative treatments for patients with limited or no therapeutic options. Investment in rngen today will drive significant progress in the next five years, creating opportunities for high-value partnerships, licensing deals, and commercialization milestones.

Near-Term Goals (Next 12-24 Months | 2025-2027)

  • Completion of IND-Enabling Studies:
    • Finalize toxicology, PK/PD, and CMC studies for KYC IND filings (BPD, NRDS, SCD) in 2026.
  • Regulatory Submissions & Approvals:
    • Submit IND applications for multiple indications to FDA and EMA.
    • Initiate pre-Phase 1 regulatory meetings to refine trial designs.
  • Phase I Clinical Trial Launch:
    • First-in-human (FIH) trials for SCD expected in 2027.
  • Expansion of IP Portfolio:
    • Additional patent filings covering KYC and compound library expanded indications, delivery methods and companion diagnostic markers.
  • Strategic Fundraising:
    • Secure Series A funding ($12.5M) to support clinical trials and manufacturing scale-up.

Mid-Term Goals (2-5 Years | 2027-2030)

  • Progression to Phase 2 Clinical Trials:
    • Demonstrate clinical efficacy of KYC in SCD, BPD, and NRDS.
    • Expand clinical pipeline to additional inflammatory and neurodegenerative diseases.
  • Pharmaceutical Partnerships & Licensing Deals:
    • Engage top-tier pharmaceutical companies for co-development or licensing agreements.
  • Scaling Manufacturing Capabilities:
    • Ensure GMP manufacturing readiness for commercial-scale production.
  • Team Expansion:
    • Strengthen R&D, regulatory, and business development teams to support clinical and commercial execution.

rngen’s scientific achievements, strong preclinical data, regulatory progress, and strategic collaborations position the company for long-term success. We have systematically de-risked KYC’s development through robust NIH funding, rigorous preclinical validation, and a well-defined regulatory pathway. With IND submissions planned for 2026 and Phase I trials commencing in 2027, now is the ideal time for investors to participate in our rapid growth and transformative potential.

Next Steps for Investors

Now is the time to invest in rngen’s mission to deliver groundbreaking treatments for underserved patients. To explore investment opportunities, contact rngen’s leadership team today: